Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study-Reference-Cited by-同舟云学术

Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study

Published:2016-03 Issue:3 Volume:3 Page:e119-e127
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Green Margaret L,Leisenring Wendy,Xie Hu,Mast T Christopher,Cui Yadong,Sandmaier Brenda M,Sorror Mohamed L,Goyal Sonia,Özkök Sezen,Yi Jessica,Sahoo Farah,Kimball Louise E,Jerome Keith R,Marks Morgan A,Boeckh Michael

Funder

National Institutes of Health grants

NIH

Publisher

Elsevier BV

Subject

Hematology

Reference29 articles.

1. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial;Marty;Lancet Infect Dis,2011

2. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation;Marty;N Engl J Med,2013

3. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation;Chemaly;N Engl J Med,2014

4. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation;Ljungman;Haematologica,2006

5. Validation of a DNAemia cutoff for preemptive therapy of cytomegalovirus infection in adult hematopoietic stem cell transplant recipients;Gerna;Bone Marrow Transplant,2008

Cited by 333 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cytomegalovirus in haematopoietic cell transplantation - The troll is still there;Best Practice & Research Clinical Haematology;2024-09

2. Comparison of Cytomegalovirus Reactivation in Children After Allogeneic Hematopoietic Cell Transplantation in 2 Transplant Eras;Transplantation Proceedings;2024-09

3. Efficacy of Letermovir for CMV Prophylaxis Following Alemtuzumab T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant.;Transplantation and Cellular Therapy;2024-09

4. UPDATE ON CYTOMEGALOVIRUS INFECTION MANAGEMENT IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS.;Mediterranean Journal of Hematology and Infectious Diseases;2024-08-31

5. CMV reactivation during pretransplantation evaluation: a novel risk factor for posttransplantation CMV reactivation;Blood Advances;2024-08-29